PTK2 and cancer: Additionally, Gq/11 activating mutations have been found to modulate YAP/TAZ activity via focal adhesion kinase (FAK), highlighting potential in inhibition of FAK as a cancer therapy, with in vitro validation in UM cell lines [245].